113 related articles for article (PubMed ID: 2170309)
1. Radiotherapy combined with low-dose cis-diammine dichloroplatinum (II) (CDDP) in inoperable nonmetastatic non-small cell lung cancer (NSCLC): a randomized three arm phase II study of the EORTC Lung Cancer and Radiotherapy Cooperative Groups.
Schaake-Koning C; Maat B; van Houtte P; van den Bogaert W; Dalesio O; Kirkpatrick A; Bartelink H
Int J Radiat Oncol Biol Phys; 1990 Oct; 19(4):967-72. PubMed ID: 2170309
[TBL] [Abstract][Full Text] [Related]
2. Toxicity of high-dose radiotherapy combined with daily cisplatin in non-small cell lung cancer: results of the EORTC 08912 phase I/II study. European Organization for Research and Treatment of Cancer.
Uitterhoeve AL; Belderbos JS; Koolen MG; van der Vaart PJ; Rodrigus PT; Benraadt J; Koning CC; González González D; Bartelink H
Eur J Cancer; 2000 Mar; 36(5):592-600. PubMed ID: 10738123
[TBL] [Abstract][Full Text] [Related]
3. Radiotherapy and cis-diammine dichloroplatinum (II) as a combined treatment modality for inoperable non-small cell lung cancer: a dose finding study.
Schaake-Koning C; Bartelink H; Adema BH; Schuster-Uitterhoeve L; van Zandwijk N
Int J Radiat Oncol Biol Phys; 1986 Mar; 12(3):379-83. PubMed ID: 3082809
[TBL] [Abstract][Full Text] [Related]
4. Radiosensitization by cytotoxic drugs. The EORTC experience by the Radiotherapy and Lung Cancer Cooperative Groups.
Schaake-Koning C; van den Bogaert W; Dalesio O; Festen J; Hoogenhout J; van Houtte P; Kirkpatrick A; Koolen M; Maat B; Nijs A
Lung Cancer; 1994 Mar; 10 Suppl 1():S263-70. PubMed ID: 8087519
[TBL] [Abstract][Full Text] [Related]
5. Phase II trial of combined radiotherapy and daily low-dose cisplatin for inoperable, locally advanced non-small cell lung cancer (NSCLC).
van Harskamp G; Boven E; Vermorken JB; van Deutekom H; Stam J; Njo KH; Karim AB; Tierie AH; Golding RP; Pinedo HM
Int J Radiat Oncol Biol Phys; 1987 Nov; 13(11):1735-8. PubMed ID: 2822636
[TBL] [Abstract][Full Text] [Related]
6. Daily low-dose cisplatin plus concurrent high-dose thoracic irradiation in locally advanced unresectable non-small-cell lung cancer: results of a phase II Southwest Oncology Group study.
Hazuka MB; Crowley JJ; Bunn PA; O'Rourke M; Braun TJ; Livingston RB
J Clin Oncol; 1994 Sep; 12(9):1814-20. PubMed ID: 8083705
[TBL] [Abstract][Full Text] [Related]
7. Weekly paclitaxel and cisplatin with concurrent radiotherapy in locally advanced non-small-cell lung cancer: a phase I study.
Frasci G; Comella P; Scoppa G; Guida C; Gravina A; Fiore F; Casaretti R; Daponte A; Parziale A; Comella G
J Clin Oncol; 1997 Apr; 15(4):1409-17. PubMed ID: 9193333
[TBL] [Abstract][Full Text] [Related]
8. A phase III study of accelerated radiotherapy with and without carboplatin in nonsmall cell lung cancer: an interim toxicity analysis of the first 100 patients.
Ball D; Bishop J; Smith J; Crennan E; O'Brien P; Davis S; Ryan G; Joseph D; Walker Q
Int J Radiat Oncol Biol Phys; 1995 Jan; 31(2):267-72. PubMed ID: 7836079
[TBL] [Abstract][Full Text] [Related]
9. Preoperative concurrent radiation therapy and cisplatinum continuous infusion in IIIa (N2) non small cell lung cancer. A pilot study.
Maggi G; Casadio C; Cianci R; Oliaro A; Molinatti M; Bretti S; Clerico M; Boidi-Trotti A; Rovea P
J Cardiovasc Surg (Torino); 1994 Aug; 35(4):341-6. PubMed ID: 7929550
[TBL] [Abstract][Full Text] [Related]
10. Phase II study of pemetrexed and cisplatin, with chest radiotherapy followed by docetaxel in patients with stage III non-small cell lung cancer.
Gadgeel SM; Ruckdeschel JC; Patel BB; Wozniak A; Konski A; Valdivieso M; Hackstock D; Chen W; Belzer K; Burger AM; Marquette L; Turrisi A
J Thorac Oncol; 2011 May; 6(5):927-33. PubMed ID: 21415776
[TBL] [Abstract][Full Text] [Related]
11. Concurrent cisplatin, etoposide, and radiotherapy for unresectable stage III nonsmall cell lung cancer: a phase II study.
Reboul F; Brewer Y; Vincent P; Chauvet B; Faure CF; Taulelle M
Int J Radiat Oncol Biol Phys; 1996 May; 35(2):343-50. PubMed ID: 8635942
[TBL] [Abstract][Full Text] [Related]
12. Alternating radiotherapy and chemotherapy for inoperable Stage III non-small-cell lung cancer: long-term results of two Phase II GOTHA trials. Groupe d'Oncologie Thoracique Alpine.
Mirimanoff RO; Moro D; Bolla M; Michel G; Brambilla C; Mermillod B; Miralbell R; Alberto P
Int J Radiat Oncol Biol Phys; 1998 Oct; 42(3):487-94. PubMed ID: 9806505
[TBL] [Abstract][Full Text] [Related]
13. Rapidly alternating radiotherapy and high dose cisplatin chemotherapy in stage IIIB non-small cell lung cancer: results of a phase I/II study.
Gandara DR; Valone FH; Perez EA; Deisseroth AB; Roach M; Ahn DK; Phillips T
Int J Radiat Oncol Biol Phys; 1991 May; 20(5):1047-52. PubMed ID: 1850719
[TBL] [Abstract][Full Text] [Related]
14. Oral vinorelbine and cisplatin as induction chemotherapy and concomitant chemo-radiotherapy in stage III non-small cell lung cancer: final results of an international phase II trial.
Krzakowski M; Provencio M; Utracka-Hutka B; Villa E; Codes M; Kuten A; Henke M; Lopez M; Bell D; Biti G; Merimsky O; Beorchia A; Riggi M; Caux NR; Pouget JC; Dubray B; David P
J Thorac Oncol; 2008 Sep; 3(9):994-1002. PubMed ID: 18758302
[TBL] [Abstract][Full Text] [Related]
15. Randomized phase II chemotherapy and radiotherapy trial for patients with locally advanced inoperable non-small-cell lung cancer: long-term follow-up of RTOG 92-04.
Komaki R; Seiferheld W; Ettinger D; Lee JS; Movsas B; Sause W
Int J Radiat Oncol Biol Phys; 2002 Jul; 53(3):548-57. PubMed ID: 12062596
[TBL] [Abstract][Full Text] [Related]
16. Different fraction schedules and combinations with chemotherapy in radiation treatment of non-small cell lung cancer.
Brattström D; Bergqvist M; Hesselius P; Wagenius G; Brodin O
Anticancer Res; 2000; 20(3B):2087-90. PubMed ID: 10928157
[TBL] [Abstract][Full Text] [Related]
17. How to improve loco-regional control in stages IIIa-b NSCLC? Results of a three-armed randomized trial from the Swedish Lung Cancer Study Group.
Nyman J; Friesland S; Hallqvist A; Seke M; Bergström S; Thaning L; Lödén B; Sederholm C; Wagenius G
Lung Cancer; 2009 Jul; 65(1):62-7. PubMed ID: 19081652
[TBL] [Abstract][Full Text] [Related]
18. A randomized study of cisplatin versus cisplatin plus vindesine for non-small cell lung carcinoma.
Kawahara M; Furuse K; Kodama N; Yamamoto M; Kubota K; Takada M; Negoro S; Kusunoki Y; Matui K; Takifuji N
Cancer; 1991 Aug; 68(4):714-9. PubMed ID: 1649683
[TBL] [Abstract][Full Text] [Related]
19. Daily low-dose cisplatin and concurrent thoracic irradiation for poor-risk patients with unresectable non-small-cell lung cancer.
Takata I; Ueoka H; Kiura K; Tabata M; Takigawa N; Katayama H; Takemoto M; Hiraki Y; Harada M; Tanimoto M
Acta Med Okayama; 2002 Oct; 56(5):261-6. PubMed ID: 12530510
[TBL] [Abstract][Full Text] [Related]
20. Combination of cisplatin and interferon-alpha 2a (Roferon-A) in patients with non-small cell lung cancer (NSCLC). An open phase II multicentre study.
Kataja V; Yap A
Eur J Cancer; 1995; 31A(1):35-40. PubMed ID: 7695976
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
